Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

SELL
$25.89 - $29.73 $111,327 - $127,839
-4,300 Reduced 37.33%
7,220 $200,000
Q4 2023

Feb 13, 2024

SELL
$26.13 - $33.94 $26,260 - $34,109
-1,005 Reduced 8.02%
11,520 $331,000
Q3 2023

Nov 13, 2023

SELL
$32.09 - $37.51 $4,492 - $5,251
-140 Reduced 1.11%
12,525 $415,000
Q3 2022

Nov 08, 2022

SELL
$43.76 - $53.42 $656 - $801
-15 Reduced 0.12%
12,665 $555,000
Q2 2022

Jul 19, 2022

SELL
$46.53 - $55.17 $1,163 - $1,379
-25 Reduced 0.2%
12,680 $665,000
Q1 2022

May 17, 2022

SELL
$45.75 - $56.69 $2,287 - $2,834
-50 Reduced 0.39%
12,705 $658,000
Q2 2020

Jul 28, 2020

SELL
$30.12 - $36.54 $3,012 - $3,654
-100 Reduced 0.78%
12,755 $417,000
Q1 2020

May 07, 2020

SELL
$27.03 - $38.62 $7,298 - $10,427
-270 Reduced 2.06%
12,855 $419,000
Q4 2019

Jan 15, 2020

SELL
$32.92 - $37.36 $1,646 - $1,868
-50 Reduced 0.38%
13,125 $514,000
Q3 2019

Nov 04, 2019

SELL
$32.49 - $42.13 $2,436 - $3,159
-75 Reduced 0.57%
13,175 $473,000
Q2 2019

Jul 24, 2019

SELL
$36.98 - $41.52 $5,546 - $6,228
-150 Reduced 1.12%
13,250 $574,000
Q1 2019

Apr 29, 2019

SELL
$37.5 - $41.2 $45,000 - $49,440
-1,200 Reduced 8.22%
13,400 $569,000
Q4 2018

Jan 24, 2019

SELL
$38.47 - $43.86 $1,923 - $2,193
-50 Reduced 0.34%
14,600 $637,000
Q2 2018

Jul 30, 2018

SELL
$32.98 - $35.16 $4,946 - $5,273
-150 Reduced 1.01%
14,650 $532,000
Q1 2018

Apr 24, 2018

SELL
$31.91 - $37.02 $6,382 - $7,404
-200 Reduced 1.33%
14,800 $526,000
Q4 2017

Feb 02, 2018

SELL
$33.26 - $35.29 $16,630 - $17,645
-500 Reduced 3.23%
15,000 $543,000
Q3 2017

Oct 26, 2017

BUY
$31.0 - $34.15 $480,500 - $529,325
15,500
15,500 $553,000

Others Institutions Holding PFE

About PFIZER INC


  • Ticker PFE
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 5,612,349,952
  • Market Cap $148B
  • Description
  • Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under ...
More about PFE
Track This Portfolio

Track Notis Mc Conarty Edward Portfolio

Follow Notis Mc Conarty Edward and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Notis Mc Conarty Edward, based on Form 13F filings with the SEC.

News

Stay updated on Notis Mc Conarty Edward with notifications on news.